Scientists have identified a biological gatekeeper in the immune system that prevents the body from producing the antibodies most critical for stopping respiratory viruses before they take hold in the nose and throat. Researchers at the University of Surrey, working with colleagues at University College London, discovered that a gene called IGHG2 acts as a consistent barrier, halting the process by which B cells switch to making protective antibodies at mucosal surfaces. The finding, published in Cell Reports Medicine, emerged from an unusually detailed study that tracked 15 healthy adults receiving their first-ever doses of the Moderna mRNA-1273 vaccine, collecting blood samples every other day for the first three weeks, then at intervals through six months.
The immune system's response to vaccines involves a carefully orchestrated process called class switch recombination, in which B cells permanently change the type of antibody they produce. Think of it as a cell moving through a series of doors: once it passes through one, it commits to the antibody type behind it. What the Surrey and UCL team discovered was that this journey almost always stalls at the IGHG2 checkpoint. Beyond that point, switching to additional antibody types became rare, confined to only a small number of specialized B cell subtypes. Across all participants—regardless of which antibodies were specific to the vaccine itself—the barrier appeared consistently, suggesting this is a fundamental rule of how human immune systems operate.
The practical consequence is stark. The mRNA vaccine triggered a robust production of IgG1 antibodies, which circulate throughout the bloodstream and reduce disease severity. But it produced very little IgA2, the antibody type that guards mucosal surfaces where respiratory viruses actually enter the body. Since SARS-CoV-2 and other respiratory pathogens breach through the nose, throat, and lungs, this limited IgA2 response offers a biological explanation for why some vaccinated people remain susceptible to infection and can continue to spread the virus, despite protection against severe disease.
The research also uncovered something unexpected about the timing of immune refinement. Class switching and somatic hypermutation—the process by which antibodies are progressively fine-tuned to better recognize their targets—had long been assumed to happen in parallel. Instead, the study found they are strikingly separate: class switching occurred rapidly in the weeks following vaccination, but meaningful antibody refinement did not become detectable until six months after the first dose. This separation has implications for how vaccine booster schedules should be timed.
A second surprise emerged after the second dose. The research team observed a substantial expansion of B cell subtypes known as "double negative" cells among vaccine-specific B cells. These cells have been associated with chronic infections, autoimmune conditions, and aging, adding a new wrinkle to understanding how the immune system responds to mRNA vaccines.
Professor Deborah Dunn-Walters, leading the research, noted that while antibody class switching has long been known to follow biological rules, "the consistency and precision of this barrier at IGHG2 in a first-time human response is new." The discovery opens a door to a practical question: can the next generation of vaccines be designed to push past this barrier and produce stronger protection precisely where it is most needed? For vaccine developers and immunologists, this research offers a roadmap for building vaccines that work not just against severe disease, but against infection itself.